Aav-Mediated Sflt-1 Gene Therapy Ameliorates Retinal Lesions in Ccl2/Cx3cr1 Deficient Mice

Jingsheng Tuo,Ji-Jing Pang,XiaoGuang Cao,Defen Shen,Jun Zhang,Abraham Scaria,Samuel C. Wadsworth,Peter Pechan,William W. Hauswirth,Chi-Chao Chan
DOI: https://doi.org/10.1096/fasebj.24.1_supplement.568.8
2010-01-01
Abstract:To test the effect of subretinal delivery of adeno‐associated virus (AAV)‐sFLT‐1 (soluble VEGF receptor‐1) on retinal lesion in ccl2−/−/cx3cr1−/− mice, a murine model of age‐related macular degeneration (AMD), the AAV5‐sFLT‐1 was injected subretinally to the right eyes of ccl2−/−/cx3cr1−/− mice. The left eyes were untreated and served as controls. Three months after the injection, the treated eyes showed significant improvements in the retinal lesions as compared to the left eyes. The average lesion scores obtained by analyzing sebsequent fundus pictures were 0.23±0.14 in the right eyes versus 0.85±0.19 in the left eyes. The histological scores between the right and left eyes from 10 pairs of eyes revealed a decrease in score in 6 pairs, no change in score in 2 pairs, and an increase in score in 2 pairs. Retinal ultrastructure also showed fewer lipofuscin granules and better preserved photoreceptors in the right eyes than the left eyes. A2E was lower in the right eyes than the left eyes. We concluded that local AAV5‐CBA‐ sFLT‐1 can either reverse or stabilize the progression of retinal lesions in Ccl2/Cx3cr1 deficient mice. Lowering retinal expression of VEGF‐A by trapping excess VEGF‐A using sFLT‐1 may result in an amelioration of the diseased retina. The findings support the beneficial effects of sFLT‐1 gene therapy for AMD. Supported by the Intramural research program of NEI
What problem does this paper attempt to address?